Skip to content
TeamCOG
TeamCOG
Citizens Observing Government
Subscribe
Try
Reports Agencies Topics Broadcasts Newsroom About Subscribe
FEDE Office of the Federal Register / National Archives and Records Administration · Rulemaking

Guidance and Procedures for Implementing Tariff Adjustments for Specialty Pharmaceuticals and Associated Pharmaceutical Ingredients and Technical Corrections to the Harmonized Tariff Schedule of the United States for Duties Imposed Under Proclamation 11020

Commerce Department, Industry and Security Bureau | Notice | This notice defines the pharmaceutical products and lists the jurisdictions that are eligible to receive an ad valorem tariff rate of zero pursuant to Presidential Proclamation 11020 of April 2, 2026, "Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States," (Proclamation 11020). These pharmaceutical products include drugs and associated ingredients where all approved indications are designated as orphan; nuclear medicines; plasma derived therapies; fertility drugs; cell therapy product; gene therapy product; antibody drug conjugates; medical countermeasures related to chemical, biological, radi.

ML Reported by Maria Lopez
September 23, 2026 · 1 min read

Guidance and Procedures for Implementing Tariff Adjustments for Specialty Pharmaceuticals and Associated Pharmaceutical Ingredients and Technical Corrections to the Harmonized Tariff Schedule of the United States for Duties Imposed Under Proclamation 11020.

The item is dated 2026-09-23.

TeamCog is carrying it as a rulemaking report from FederalRegister.gov published documents API.

Commerce Department, Industry and Security Bureau | Notice | This notice defines the pharmaceutical products and lists the jurisdictions that are eligible to receive an ad valorem tariff rate of zero pursuant to Presidential Proclamation 11020 of April 2, 2026, "Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States," (Proclamation 11020).

These pharmaceutical products include drugs and associated ingredients where all approved indications are designated as orphan; nuclear medicines; plasma derived therapies; fertility drugs; cell therapy product; gene therapy product; antibody drug conjugates; medical countermeasures related to chemical, biological, radi…

The handoff preserves the official source citation and source-completeness evidence supplied by discovery.

Editors should keep any claims tied to that source record.

Official Source

FederalRegister.gov published documents API. Accessed 2026-09-23T15:00:02.226Z.